Pfizer tests combined COVID-19 and flu shot
/cloudfront-us-east-1.images.arcpublishing.com/gray/JXFCHI6ACRGGRF7HCSH2SKMC4U.jpg)
(CNN) - Pfizer has launched its study of a combination COVID-19 and flu vaccine.
On Thursday, Pfizer and its German partner, BioNTech, announced that the first participant has received a dose in Phase 1 of the trial.
The shot contains Pfizer’s updated, bivalent COVID-19 boosters and its flu vaccine.
The bivalent booster targets the original COVID-19 strain and two omicron subvariants.
Other vaccine makers also are studying combination vaccines.
Novavax announced this month that its combination COVID-19 and flu vaccine candidate generated immune responses against coronavirus and influenza strains in an early clinical trial.
Moderna is also developing a combined flu and COVID-19 vaccine and another combination vaccine targeting flu, COVID-19 and RSV.
Copyright 2022 CNN Newsource. All rights reserved.
/cloudfront-us-east-1.images.arcpublishing.com/gray/M7KYIXMCWBN6TODWOMMFFG34VI.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/gray/PLZRU2Z4HRBOJAEXNENPLP7BDM.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/gray/NJXE6H7ZSNDTRAGTTOGOYBHE3Q.jpg)
/cloudfront-us-east-1.images.arcpublishing.com/gray/EYBSSS7BYFHYXHL6IPRXT2XQZM.png)
/cloudfront-us-east-1.images.arcpublishing.com/gray/QS26RUDJCVBZZKH2ONFDABKZ44.png)
/cloudfront-us-east-1.images.arcpublishing.com/gray/2ASU7KAVOTGGLG6YUXYMUSM7KA.jpg)
/cloudfront-us-east-1.images.arcpublishing.com/gray/WGX4RQN4WVHJPK26DWAMWOLO3U.jpg)
/cloudfront-us-east-1.images.arcpublishing.com/gray/UUQHUUGFUEQ7HGRVKKI4T5J7KM.jpg)
/cloudfront-us-east-1.images.arcpublishing.com/gray/K6REUM7OBOSAL3VXTJKQMUXCAU.jpg)
/cloudfront-us-east-1.images.arcpublishing.com/gray/44V5G2N5DRFSZIATZYSXUICWAA.jpg)